The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Measuring ctDNA With ddPCR May Help Drive Precision Medicine in Pancreatic Cancer
April 9th 2021A recent review took a look at the promise of measuring circulating tumor DNA (ctDNA) with digital-droplet PCR (ddPCR) in pancreatic ductal adenocarcinoma (PDAC) as the landscape of this cancer continues to shift toward personalized, precision treatment.
Read More
ddPCR May Be More Accurate Than Traditional RQ-PCR for Measuring MRD in ALL
April 3rd 2021Study findings indicate that droplet digital polymerase chain reaction (ddPCR) may be more accurate than real-time quantitative PCR in measuring minimal residual disease (MRD) among pediatric patients with acute lymphoblastic leukemia (ALL), particularly in late follow-up time points.
Read More
Study Makes the Case for NGS Testing as SOC in Certain Patients With Advanced Cancer
March 20th 2021The results showed that in half of patients with cancers of unknown origin, next-generation sequencing located the primary site of origin and, in those who were matched to a therapy, half achieved a clinical benefit.
Read More
The Untapped Potential of Cell and Gene Therapy
February 16th 2021Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.
Read More
Managing the “Knowledge Explosion” a Key Challenge of Precision Oncology
December 20th 2020Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.
Read More
From Making Oncology Clinical Pathways Multidisciplinary, to Adding the Patient’s Voice
December 18th 2020According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.
Read More